What is ICD-10 code C83.7A?

C83.7A is the ICD-10-CM diagnosis code for Burkitt lymphoma, in remission. Burkitt lymphoma that is in remission, meaning the cancer is no longer detectable or has responded well to treatment. It belongs to the ICD-10-CM chapter for neoplasms (c00-d49). C83.7A is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. C83.7A is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. C83.7A is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. C83.7A is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

Which HCC does C83.7A map to under V28?

C83.7A maps to CMS-HCC V28 HCC 20 (Lung and Other Severe Cancers). The category numbers, labels, and conditions come from the CMS-HCC V28 model file for payment year 2026.

2026 ICD-10-CM C83.7A: Burkitt lymphoma

C83.7A maps to CMS-HCC V28 20. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · HCC coding software

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC83.7A

Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C83.7A

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Burkitt lymphoma, in remission

Burkitt lymphoma that is in remission, meaning the cancer is no longer detectable or has responded well to treatment.

Buddy Insight

Burkitt lymphoma in remission indicates the patient has completed treatment and the disease is no longer actively detectable, though ongoing surveillance is required due to risk of relapse.

Overview Risk Models Code Book Documentation Audit Notes Edition comparison

CMS-HCC V28

Mapped

HCC 20

Lung and Other Severe Cancers

Code-level coefficient reference

CMS-HCC V24

Historical

Not used for standard CY2026 Medicare Advantage payment. Select a historical period to review V24.

Not used for CY2026 payment

ACA/HHS

Mapped

HCC 010

HHS-HCC 010 adult, RAF varies...

Code-level coefficient reference

ESRD/PACE

Mapped

HCC 10

Lymphoma and Other Cancers

Code-level coefficient reference

RXHCC

Mapped

HCC 21

Lymphomas and Other Hematolog...

Code-level coefficient reference

Code Book Path

Official

C83Non-follicular lymphoma C83.7Burkitt lymphoma C83.7ABurkitt lymphoma, in remission

Inclusion Terms

Official

Atypical Burkitt lymphomaInherited from C83.7
Burkitt-like lymphomaInherited from C83.7

Excludes 2

Official

Kaposi's sarcoma of lymph nodes (C46.3)Inherited from C81-C96
secondary and unspecified neoplasm of lymph nodes (C77.-)Inherited from C81-C96
secondary neoplasm of bone marrow (C79.52)Inherited from C81-C96
secondary neoplasm of spleen (C78.89)Inherited from C81-C96

Related Codes

Official

C83.70Burkitt lymphoma, unspecified site C83.71Burkitt lymphoma, lymph nodes of head, face, and neck C83.72Burkitt lymphoma, intrathoracic lymph nodes C83.73Burkitt lymphoma, intra-abdominal lymph nodes C83.74Burkitt lymphoma, lymph nodes of axilla and upper limb

Includes

Official

No Includes notes are included in this display for C83.7A. Check the code and parent instructions in the Code Book.

Excludes 1

Official

personal history of non-Hodgkin lymphoma (Z85.72)Inherited from C83, C83.7
mature B-cell leukemia Burkitt type (C91.A-)Inherited from C83, C83.7

Code First

Official

No Code First sequencing instructions are included in this display for C83.7A. Check the code and parent instructions in the Code Book.

Use Additional

Official

No Use Additional Code instructions are included in this display for C83.7A. Check the code and parent instructions in the Code Book.

Code Also

Official

No Code Also instructions are included in this display for C83.7A. Check the code and parent instructions in the Code Book.

Buddy Documentation Tip

HCC Buddy guidance

Explicit provider documentation stating 'remission' — complete or partial remission must be stated

Supporting evidence such as negative PET/CT, normal labs, or pathology confirmation of no residual disease

History of confirmed Burkitt lymphoma diagnosis

Current surveillance or follow-up plan documented

MEAT Support

HCC Buddy guidance

Explicit provider documentation stating 'remission' — complete or partial remission must be stated

Supporting evidence such as negative PET/CT, normal labs, or pathology confirmation of no residual disease

History of confirmed Burkitt lymphoma diagnosis

Current surveillance or follow-up plan documented

Audit Caution

HCC Buddy guidance

Using active disease site-specific codes when provider clearly documents remission status

Prematurely coding Z85.79 (personal history) when the patient is still under active oncologic surveillance for Burkitt lymphoma

Not distinguishing between 'no evidence of disease' (which supports remission coding) and 'stable disease' (which may still be active)

Failing to code remission status when provider uses equivalent terms like 'complete response' or 'no evidence of disease'

Common Mistakes

HCC Buddy guidance

C83.70-C83.79 — Active Burkitt lymphoma by site: Use these codes only when disease is active, not in remission

Z85.79 — Personal history of other lymphoid, hematopoietic and related tissue malignancies: Use only when the lymphoma is considered cured and no longer being monitored as active disease; C83.7A is appropriate while still under active oncology surveillance

C83.8A — Other non-follicular lymphoma, in remission: Different lymphoma subtype; verify pathology confirms Burkitt specifically

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C83.7A an HCC code?

Yes. C83.7A (Burkitt lymphoma, in remission) maps to HCC 20, Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 1.136. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.

Coder answer: C83.7A is billable and maps to V28 HCC 20, Lung and Other Severe Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code: C83.7A
Description: Burkitt lymphoma, in remission
HCC (V28): HCC 20 — Lung and Other Severe Cancers
RAF reference coefficient: 1.136
Billable: Yes
Payment year: 2026

HCC Category Mapping

V28HCC 20, Lung and Other Severe Cancers

1.136

ESRDHCC 10, Lymphoma and Other Cancers

Not separately weighted

RxHCCHCC 21, Lymphomas and Other Hematologic Cancers

Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work C83.7A in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT review for C83.7A

For C83.7A, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C83.7A is the ICD-10-CM diagnosis code for burkitt lymphoma, in remission. Burkitt lymphoma that is in remission, meaning the cancer is no longer detectable or has responded well to treatment. C83.7A sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C83.7A maps to Lung and Other Severe Cancers (HCC 20) with a source-labeled community, non-dual, aged reference coefficient of 1.136. No V24 mapping is shown for C83.7A; use the applicable model and payment year when reviewing the V28 mapping. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.

Use this code only when documentation explicitly states the patient is in remission or complete response. For C83.7A, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C83.7A sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Use this code only when documentation explicitly states the patient is in remission or complete response
•This code can be used regardless of the anatomical site originally involved

Clinical Significance

Burkitt lymphoma in remission indicates the patient has completed treatment and the disease is no longer actively detectable, though ongoing surveillance is required due to risk of relapse. This code is important for risk adjustment because it captures the ongoing complexity of managing a patient with a history of this highly aggressive malignancy. Even in remission, patients require regular imaging, laboratory monitoring, and assessment for late treatment effects.

Documentation Requirements

✓Explicit provider documentation stating 'remission' — complete or partial remission must be stated
✓Supporting evidence such as negative PET/CT, normal labs, or pathology confirmation of no residual disease
✓History of confirmed Burkitt lymphoma diagnosis
✓Current surveillance or follow-up plan documented
✓Date of last treatment and duration of remission if available

Commonly Confused Codes

•C83.70-C83.79: Active Burkitt lymphoma by site: Use these codes only when disease is active, not in remission
•Z85.79: Personal history of other lymphoid, hematopoietic and related tissue malignancies: Use only when the lymphoma is considered cured and no longer being monitored as active disease; C83.7A is appropriate while still under active oncology surveillance
•C83.8A: Other non-follicular lymphoma, in remission: Different lymphoma subtype; verify pathology confirms Burkitt specifically